| Microorganism |
MIC50
(μg/ml) |
MIC90
(μg/ml) |
Range
(μg/ml) |
Antimicrobial |
Reference |
| Staphylococcus caprae (coagulase-negative + oxacillin-susceptible) |
0.12 |
0.25 |
≤0.06 － >8 |
Clindamycin (Cleocin)  |
412 |
| Staphylococcus caprae (coagulase-negative + oxacillin-susceptible) |
0.12 |
2 |
≤0.03 － >4 |
Gatifloxacin (Tequin) |
412 |
| Staphylococcus caprae (coagulase-negative + oxacillin-susceptible) |
>0.25 |
>2 |
0.06 － >2 |
Ciprofloxacin (Cipro, Ciproxin, Ciprobay) |
412 |
| Staphylococcus caprae (coagulase-negative + oxacillin-susceptible) |
≤0.5 |
≤0.5 |
≤0.5 － >8 |
Imipenem |
412 |
| Staphylococcus caprae (coagulase-negative + oxacillin-susceptible) |
0.5 |
1 |
≤0.5 － 8 |
Zosyn |
412 |
| Staphylococcus caprae (coagulase-negative + oxacillin-susceptible) |
0.5 |
2 |
≤0.12 － 8 |
Cefepime (Maxipime) |
412 |
| Staphylococcus caprae (coagulase-negative + oxacillin-susceptible) |
>0.5 |
>2 |
≤0.5 － >2 |
Co-trimoxazole (Trimethoprim-sulfamethoxazole, TMP-SMX) |
412 |
| Staphylococcus caprae (coagulase-negative + oxacillin-susceptible) |
1 |
2 |
≤0.12 － 4 |
Vancomycin (Vancocyn, Lyphocin) |
412 |
| Staphylococcus caprae (coagulase-negative + oxacillin-susceptible) |
2 |
4 |
≤0.25 － >32 |
Ceftriaxone (Rocephin) |
412 |
| Staphylococcus caprae (coagulase-negative + oxacillin-susceptible) |
4 |
8 |
0.25 － >16 |
Ceftazidime (Ceptaz, Fortaz, Tanicef) |
412 |
| Staphylococcus caprae (LQC 5091) |
- |
- |
2 － ? |
Ampicillin (Omnipen) |
836 |
| Staphylococcus caprae (LQC 5091) |
- |
- |
2 － ? |
Erythromycin (E-mycin, Ery-tab, Benzamycin) |
836 |
| Staphylococcus caprae (LQC 5091) |
- |
- |
8 － ? |
Streptomycin |
836 |
| Staphylococcus caprae (LQC 5091) |
- |
- |
16 － ? |
Bacitracin (Baci-IM) |
836 |
| Staphylococcus caprae (LQC 5091) |
- |
- |
32 － ? |
Chloramphenicol (Chloromycetin) |
836 |
| Staphylococcus caprae (LQC 5091) |
- |
- |
64 － ? |
Novobiocin (Albamycin) |
836 |
| Staphylococcus caprae (LQC 5091) |
- |
- |
128 － ? |
Tetracycline (Sumycin, Achromycin V, Steclin) |
836 |